Extracorporeal Membrane Oxygenation Market Size By Modality (Venoarterial, Veno-venous, Arteriovenous), By Application (Cardiac, Respiratory, Extracorporeal Cardiopulmonary Resuscitation), By Patient Population (Infant, Pediatric, Adult), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2021 - 2027

Published Date: Jul 2021  |  Report ID: GMI2720  |  Authors: Sumant Ugalmugle, Rupali Swain

Report Format: PDF   |   Pages: 150   |   Base Year: 2020




Summary Table of Contents Industry Coverage Methodology

Industry trends

Extracorporeal Membrane Oxygenation (ECMO) Market size exceeded USD 500 million in 2020 and is anticipated to grow at a CAGR of over 2.7% between 2021 and 2027. Increasing adoption rate of ECMO has stimulated technological advancements in these devices. The major advancement include miniaturisation of ECMO components such as hollow pumps, oxygenators, and heparin coated cannula used for various surgeries. Thus, miniaturization of ECMO components have increased its portability that aids in transportation of critically ill patients, thereby increasing its demand.
 

Extracorporeal Membrane Oxygenation Market Overview

Get more details on this report - Request Free Sample PDF
 

ECMO devices are used in extreme situations when other supportive care has been unsuccessful. ECMO device is used for various applications such as distressed respiratory syndrome, congenital diaphragmatic hernia, pulmonary hypertension, severe pneumonia, and cardiac arrest. Moreover, increasing incidence of asthma and chronic obstructive pulmonary disease (COPD) has significantly increased the usage of ECMO in various healthcare settings.
 

COVID-19 pandemic has fuelled the usage of ECMO machine worldwide

The sudden surge in COVID-19 cases coupled with rising number of critically ill patients requiring extra life support have escalated the demand for ECMO machines. The extracorporeal life support has been the most preferred treatment option for patient with severe acute respiratory distress syndrome.
 

Increasing number of government supportive policies and speedy FDA approval of ECMO machine for emergency use have propelled the market significantly. In April 2020, the U.S. FDA approved guidelines to expand the availability and usage of ECMO devices. The FDA included a list of all the devices that can be used for ECMO therapy. Thus, favourable reimbursement policies and speedy approval of devices for emergency use will foster the market during the forecast period. Additionally, several companies also expanded their manufacturing capabilities to cater to the growing demand for assistive technologies, thereby impacting the market growth.
 

Rising incidence of cardiac disorder coupled with technological advancement are the factors augmenting the market expansion

Extracorporeal Membrane Oxygenation Market Size

Get more details on this report - Request Free Sample PDF

 

The veno-arterial (VA) extracorporeal membrane oxygenation market was valued at USD 234.1 million in 2020. The VA ECMO circuit finds its application in patients with cardiac arrest and helps in algorithmic life support strategies to restore blood circulation. These ECMO circuit perform dual function of providing hemodynamic support and gaseous exchange.
 

Veno-arterial ECMO can be used to treat patients suffering from pulmonary embolism and pulmonary hypertension, especially in the case of acute decomposition. Thus, increasing applications and acceptance will fortify the demand VA extracorporeal membrane oxygenation on the coming years.
 

Increasing number of patients suffering from severe cardiac disorders will boost the market revenue

The cardiac segment is estimated to register a growth rate of 5.2% through 2027. The ECMO systems are used to treat severe cardiac conditions such as cardiac shock or arrest wherein the ECMO machine serves as an artificial heart. Thus, increasing incidence of cardiac disorders coupled with significant rise in the usage of ECMO machine will drive the segment growth during the forecast period.
 

Rising geriatric population base suffering various chronic diseases will positively impact the segment expansion

The adult segment accounted for USD 200 million in 2020. Increasing geriatric population and rising number of adults suffering from various chronic and infectious diseases will augment the demand for ECMO procedures. In addition, advancements in ECMO technology has increased its application in the treatment of adults owing to growing effect of COVID-19.
 

Advances in includes pumpless veno arterial extracorporeal gas support devices, respiratory dialysis, and double lumen cannula. Thus, such technological advancements help doctors in planning effective ECMO treatment while considering factors such as degree of organ failure, comorbid condition, weight, and the age of the patient, thereby increasing its preference.
 

Presence of large patient population and availability of several ECMO centres will spur the demand for ECMO machines in North America region

North America ECMO market captured 60% of the revenue share in 2020. The increasing burden of chronic obstructive pulmonary disease, COVID-19 infection, cardiopulmonary disease, and respiratory failure contribute to the industry growth. In 2020, pandemic became the leading cause of death for population aged 45 to 84 years. The ECMO machine replaces the functions of lungs and/ or heart, thereby allow these critically ill adult patient to recover and rest.
 

Speedy FDA approval and product launch to broaden accessibility assist the companies in business expansion

The global market is dominated by companies such as Medtronic, Terumo Corporation, Alung Technologies, and Abbott Laboratories. These players are actively involved in product launches and technological innovation to stay competitive in the market.
 

Some of the recent industry developments:

  • In May 2020, ALung Technologies, Inc. announced the commercial development of its breakthrough next-generation artificial lung. The device is based upon intellectual property licenced to ALung Technologies, Inc from the University of Pittsburgh.
     
  • In June 2020, Medtronic announced its artificial lung therapy available for COVID-19 treatment. The ECMO is described as an artificial pump that pumps blood from person’s body to an oxygenator. Medtronic has device that is FDA cleared for ECMO procedure of up to 6 hours.
     

The extracorporeal membrane oxygenation (ECMO) market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027 for the following segments:

Market, By Modality

  • Venoarterial
  • Veno-venous
  • Arterio-venous

Market, By Application

  • Cardiac
  • Respiratory
  • Extracorporeal cardiopulmonary resuscitation (ECPR)

Market, By Patient Population

  • Infant
  • Pediatric
  • Adult

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
  • Asia Pacific
    • China
    • Japan
    • India
    • Taiwan
    •  
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Qatar
    • UAE
       

Frequently Asked Questions (FAQ) :

The market size of extracorporeal membrane oxygenation had reached more than USD 500 million in 2020 and will attain a CAGR of over 2.7% up to 2027.
The veno-arterial (VA) modality segment exceeded USD 234.1 million in 2020 and will grow with the increasing prevalence of cardiac arrests.
The cardiac application segment will grow at around 5.2% rate through 2027 driven by the growing need in the treatment of cardiac conditions such as cardiac shock or arrests.
The overall industry share from the adult segment surpassed USD 200 million in 2020 and expand with the booming geriatric population and the rising instances of chronic and infectious diseases.
North America captured more than 60% of the revenue share in 2020 owing to the prevalence of chronic obstructive pulmonary diseases in the region.

Premium Report Details

  • Published Date: Jul 2021
  • Pages: 150
  • Tables: 177
  • Charts / Figures: 13
  • Companies covered: 14
  • Countries covered: 18

Get a report that explains COVID-19 impact on this market

Buy Now

Need a Discount? Get in touch with us for special pricing

Request Discount

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X